These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 23975081)

  • 81. Preoperative Chemoradiotherapy in Locally Advanced Bulky Squamous Cell Carcinoma of the Uterine Cervix.
    Nakao Y; Hashiguchi M; Nishiyama S; Aihara S; Iwasaka T; Yokoyama M
    Int J Gynecol Cancer; 2017 Nov; 27(9):1943-1948. PubMed ID: 28786876
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Application value of reduced field intensity modulated radiation therapy for advanced cervical cancer].
    DU XL; Sheng XG; Wang C; Yu H; Song QQ; Pan CX
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):925-31. PubMed ID: 24506963
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    McCormack M; Eminowicz G; Gallardo D; Diez P; Farrelly L; Kent C; Hudson E; Panades M; Mathew T; Anand A; Persic M; Forrest J; Bhana R; Reed N; Drake A; Adusumalli M; Mukhopadhyay A; King M; Whitmarsh K; McGrane J; Colombo N; Mak C; Mandal R; Chowdhury RR; Alamilla-Garcia G; Chávez-Blanco A; Stobart H; Feeney A; Vaja S; Hacker AM; Hackshaw A; Ledermann JA;
    Lancet; 2024 Oct; 404(10462):1525-1535. PubMed ID: 39419054
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 85. High dose simultaneous integrated boost for node positive cervical cancer.
    Jayatilakebanda I; Tsang YM; Hoskin P
    Radiat Oncol; 2021 May; 16(1):92. PubMed ID: 34001158
    [TBL] [Abstract][Full Text] [Related]  

  • 86. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk.
    Ahmed RS; Kim RY; Duan J; Meleth S; De Los Santos JF; Fiveash JB
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):505-12. PubMed ID: 15380585
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
    Folkert MR; Shih KK; Abu-Rustum NR; Jewell E; Kollmeier MA; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Feb; 128(2):288-93. PubMed ID: 23159818
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Concomitant Chemoradiotherapy With Image-guided Pulsed Dose Rate Brachytherapy as a Definitive Treatment Modality for Early-stage Cervical Cancer.
    Refaat T; Castelain B; Small W; Elsaid A; Lotfy N; Lartigau E; Nickers P
    Am J Clin Oncol; 2015 Jun; 38(3):289-93. PubMed ID: 23799285
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
    Ma K; Yang YH; Yang X; Feng ZY; Liu TY; Wen HW; Liao QP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):910-5. PubMed ID: 24343073
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
    Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.
    Vandecasteele K; Tummers P; Makar A; van Eijkeren M; Delrue L; Denys H; Lambert B; Beerens AS; Van den Broecke R; Lambein K; Fonteyne V; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):408-14. PubMed ID: 22377596
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prophylactic extended-field irradiation for locally advanced cervical cancer.
    Li H; Wang S; Liu Y; Wang T; Jin S; Liu Z
    Gynecol Oncol; 2022 Sep; 166(3):606-613. PubMed ID: 35868881
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S; Isohashi F; Yokoi T; Takemura M; Yoshino K; Shiki Y; Ito K; Enomoto T; Ogawa K; Kimura T
    Gynecol Oncol; 2016 May; 141(2):240-246. PubMed ID: 26883141
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
    Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix.
    Uno T; Mitsuhashi A; Isobe K; Yamamoto S; Kawakami H; Ueno N; Usui H; Tate S; Kawata T; Ito H
    Int J Gynecol Cancer; 2008; 18(1):80-4. PubMed ID: 17466053
    [TBL] [Abstract][Full Text] [Related]  

  • 96. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study.
    Mutic S; Malyapa RS; Grigsby PW; Dehdashti F; Miller TR; Zoberi I; Bosch WR; Esthappan J; Low DA
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):28-35. PubMed ID: 12504033
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
    Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
    Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
    Kim YS; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
    Gynecol Oncol; 2008 Jan; 108(1):195-200. PubMed ID: 17963825
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy.
    Yamamoto T; Umezawa R; Tokunaga H; Kubozono M; Kozumi M; Takahashi N; Matsushita H; Kadoya N; Ito K; Sato K; Tsuji K; Shimada M; Jingu K
    J Radiat Res; 2020 May; 61(3):470-478. PubMed ID: 32100833
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.